Module

State-of-the-Art Management of Sexually Transmitted Diseases

Source: HIV/AIDS Annual Update 2009

State-of-the-Art Management of Sexually Transmitted Diseases

Program Director: Kimberly Y. Smith, MD, MPH

Faculty:

Jeanne Marrazzo, MD, MPH

CREDIT INFORMATION

Release Date: 05/18/09

Expiration Date: 05/17/10

Physicians: maximum of 0.75 AMA PRA Category 1 Credits™

Registered Nurses: 0.9 Nursing contact hours

Pharmacists: 0.9 contact hours (0.09 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe recent trends in the incidence of syphilis in HIV-infected patients
Explain the interpretation of serologic tests for syphilis, including treponemal enzyme immunoassays, in the HIV-infected patient
List therapeutic options for management of Neisseria gonorrhoeae, including options for patients intolerant of cephalosporins
Discuss the relationship between herpes simplex virus type 2 infection and HIV transmission
Name at least 2 other sexually transmitted diseases for which HIV providers should consider testing

Topics covered include:

Syphilis: Recent Trends and Diagnostic Challenges
Gonorrhea: The Narrowing of Therapeutic Options
Genital Herpes: New Insights Into Pathogenesis, but Disappointing Results in HIV Prevention Efforts
New (?), Neglected, and Uncommon STDs: Don’t Forget About Them!
Early Detection of STDs in HIV-Infected Patients: The Critical Role of Screening
Summary—Implications for Clinical Practice

Abstract

Click here to view abstract

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.